Voyager Therapeutics, Inc. financial data

Symbol
VYGR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
75 Hayden Avenue, Lexington, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 697 % +14.5%
Debt-to-equity 32 % -43.4%
Return On Equity -19.9 % -131%
Return On Assets -15.1 % -137%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.2M shares +1.5%
Common Stock, Shares, Outstanding 54.7M shares +24.3%
Entity Public Float 408M USD -16.6%
Common Stock, Value, Issued 55K USD +25%
Weighted Average Number of Shares Outstanding, Basic 57.7M shares +34%
Weighted Average Number of Shares Outstanding, Diluted 57.7M shares +29.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 80M USD -68%
Research and Development Expense 127M USD +38.2%
General and Administrative Expense 35.9M USD +0.27%
Operating Income (Loss) -83.3M USD -168%
Nonoperating Income (Expense) 19M USD +61.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -64.3M USD -148%
Income Tax Expense (Benefit) 665K USD -52.8%
Net Income (Loss) Attributable to Parent -65M USD -149%
Earnings Per Share, Basic -1.13 USD/shares -137%
Earnings Per Share, Diluted -1.13 USD/shares -138%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71.4M USD +3.73%
Marketable Securities, Current 195M USD +20.5%
Cash, Cash Equivalents, and Short-term Investments 332M USD +44%
Other Assets, Current 2.87M USD +9.36%
Assets, Current 277M USD -13.4%
Property, Plant and Equipment, Net 14.3M USD -13.2%
Operating Lease, Right-of-Use Asset 33.3M USD +147%
Assets 393M USD +11.9%
Accounts Payable, Current 4M USD +149%
Employee-related Liabilities, Current 6.75M USD +2.09%
Accrued Liabilities, Current 14.2M USD -15.8%
Contract with Customer, Liability, Current 24.4M USD -43.1%
Liabilities, Current 49.8M USD -22.8%
Contract with Customer, Liability, Noncurrent 6M USD -81.4%
Operating Lease, Liability, Noncurrent 36.5M USD +114%
Other Liabilities, Noncurrent 37.5M USD +107%
Liabilities 93.3M USD -18.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -407K USD -748%
Retained Earnings (Accumulated Deficit) -326M USD -24.9%
Stockholders' Equity Attributable to Parent 300M USD +26.8%
Liabilities and Equity 393M USD +11.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 58.8M USD -52.4%
Net Cash Provided by (Used in) Financing Activities 113M USD +260%
Net Cash Provided by (Used in) Investing Activities -96.1M USD -763%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 54.7M shares +24.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 75.6M USD -55.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 74.2M USD +5.46%
Deferred Tax Assets, Valuation Allowance 106M USD +28.1%
Deferred Tax Assets, Gross 118M USD +32.2%
Operating Lease, Liability 43.7M USD
Depreciation 1.2M USD +11.3%
Payments to Acquire Property, Plant, and Equipment 2.14M USD +321%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -65.4M USD -149%
Lessee, Operating Lease, Liability, to be Paid 52.6M USD
Property, Plant and Equipment, Gross 30.3M USD -4%
Operating Lease, Liability, Current 7.23M USD +126%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.98M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 9.91M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.87M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.76M USD
Deferred Tax Assets, Operating Loss Carryforwards 4.24M USD -69.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 8M USD
Additional Paid in Capital 626M USD +25.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 11.9M USD +84.5%
Share-based Payment Arrangement, Expense 14.8M USD +32.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%